GALR1 is a G protein-coupled receptor for the neuropeptide galanin that mediates inhibition of adenylate cyclase activity 1. The receptor is widely distributed in the central and peripheral nervous systems, with expression in approximately 19% of norepinephrine neurons in the locus coeruleus, where GalR1 agonists directly inhibit neuronal activity 2. GALR1 plays protective roles in several pathophysiological conditions. Variants in GALR1 are associated with reduced nicotine dependence risk, suggesting the receptor mediates protective effects against drug addiction 3. In cardiac physiology, GALR1 is less critical than GALR2 for atrial fibrillation susceptibility, as GALR2 (not GALR1) knockout increases AF incidence through CREB-dependent upregulation of potassium channels and impaired calcium handling 4. In hepatic lipid metabolism, increased GALR1 expression promotes lipid accumulation through PI3K/AKT pathway activation and SREBP1 upregulation; conversely, GALR1 antagonism reduces dyslipidemia in circadian disruption models 5. Clinically, reduced GALR1 expression serves as a biomarker for invasive non-functional pituitary neuroendocrine tumors and correlates with enhanced tumor cell proliferation and invasiveness 6. In breast cancer cells, GALR1 upregulation promotes proliferation and migration through PI3K/AKT and MAPK/ERK pathway activation 7. Conversely, common genetic variants in GALR1 do not contribute significantly to early-onset obesity 8.